BRAF and melanoma: In a phase III clinical of patients with advanced melanoma harboring the BRAFV600E mutation, the combination of BRAF and MEK inhibitors (dabrafenib plus trametinib) increased the 3-year relapse-free survival rate compared to placebo treatment (58% vs. 39%) (Long et al., 2017).